Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

86.66 +0.77 (+0.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,336,033
Open 86.22
Bid (Size) 86.53 (1)
Ask (Size) 86.77 (4)
Prev. Close 85.89
Today's Range 85.86 - 86.88
52wk Range 60.47 - 86.88
Shares Outstanding N/A
Dividend Yield 1.07%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AstraZeneca Threatens To Move Vaccine Production Amid Reduced State Support
AstraZeneca may relocate its vaccine manufacturing site from Merseyside to Philadelphia as the UK government considers slashing state aid from £90 million to £40 million, jeopardizing Britain's life... 
Via Benzinga
Biotech Bull Market: 3 Ways To Play It
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. 
Via Talk Markets
Topics Economy
Exposures Interest Rates

Performance

YTD
+26.70%
+26.70%
1 Month
+8.72%
+8.72%
3 Month
+10.34%
+10.34%
6 Month
+31.64%
+31.64%
1 Year
+27.65%
+27.65%

More News

Read More
Ozempic And Wegovy Linked to Increased Suicidal Thoughts In Observational Study, But Results Are Contested
Via Benzinga
Johnson & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave
Via Benzinga
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Is NASDAQ:AZN a Suitable Choice for Quality Investing?
Via Chartmill
FDA Approves AstraZeneca's Blockbuster Cancer Drug, Imfinzi, In Combination With Chemo For Non-Small Cell Lung Cancer
Via Benzinga
Exposures Product Safety
IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery
From AstraZeneca
Via Business Wire
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
Via Investor's Business Daily
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US
From AstraZeneca
Via Business Wire
AstraZeneca's $578M Vaccine Plant In Doubt As UK Government Cuts Funding
Via Benzinga
Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs
Via MarketBeat
Topics ETFs
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
Via InvestorPlace
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows
Via Benzinga
Exposures COVID-19
New European Regulations Could Hinder Rare Disease Treatments, Pharma Industry Raises Concerns Over Stricter Clinical Trial Rules
Via Benzinga
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
Via Benzinga
Exposures COVID-19
EXCLUSIVE: Penny Stock Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets
Via Benzinga
Top Analyst Reports For AstraZeneca, TotalEnergies & ConocoPhillips
Via Talk Markets
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
Via Benzinga
Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market
Via The Motley Fool
Bank Of England Reduces 16-Year High Interest Rates In Divided Decision As Inflation Hits 2%
Via Benzinga
Topics Economy
Exposures Interest Rates
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Via InvestorPlace
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Via Benzinga
Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial
From AstraZeneca
Via Business Wire
UK Agency Says AstraZeneca's Breast Cancer Drug Enhertu Is Expensive, CEO Pascal Soriot Urges Review Of Drug Pricing Assessment
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.